|
|
Article: Latest Clinical, Socioeconomic Data on Migraine Medications Presented by Glaxo Wellcome at Scientific Meeting
- Article from:
- PR Newswire
- Article date:
- June 19, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- News Marks Latest Developments from the 'World Leader in Migraine
Research' --
NEW YORK, June 19 /PRNewswire/ -- Clinical study data presented on Amerge(R) (naratriptan), a migraine therapy in development from Glaxo Wellcome Inc., (NYSE: GLX) suggest the tablet is effective as early as one hour and has a long duration of action (72-81 percent of patients achieved relief for 24 hours with a single dose). Extensive clinical trials with Amerge have consistently shown the 2.5 mg dose is well tolerated because it has a side- effect profile equal to placebo.
Additionally, data presented on the nasal formulation ...